(Reuters) – British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
The medicine is used to treat and prevent progression of steatotic liver disease.
Under the terms of the agreement, GSK will pay $1.2 billion upfront, with potential for additional success-based milestone payments totalling $800 million. (This story has been corrected to say the deal value is up to $2 bln, not $1.2 bln, in the headline and paragraph 1)
(Reporting by Chandini Monnappa in Bengaluru; Editing by Mrigank Dhaniwala)
Comments